In a randomised double-blind, placebo-controlled trial of 100 overweight/obese subjects with T2DM (average age: 54.72 ± 8.34 years; BMI ≥ 24.0; curcuminoids (300 mg/day; n = 50) supplementation for 12 weeks significantly reduced fasting glucose, HbA1c and homeostasis model assessment insulin resistance (HOMA-IR) with decreased levels of serum free fatty acids (FFAs) and TG, and increased lipoprotein lipase (LPL) activity compared with a placebo. This evidence concerns the gene LPL and type 2 diabetes mellitus.